VolitionRX (VNRX) AI Stock Analysis

• Market Cap: $39.51M
• Dividend Yield: N/A
• Average Volume (3M): 995.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.52
• Revenue Growth: 14.48%
• EPS Growth: 36.83%
• Country: US
• Employees: 85
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.05
• Shares Outstanding: 122,801,575
• 10 Day Avg. Volume: 825,693
• 30 Day Avg. Volume: 995,625
• PEG Ratio: 0.05
• Price to Book (P/B): -2.08
• Price to Sales (P/S): 42.09
• P/FCF Ratio: -1.96
• Enterprise Value/Market Cap: 2.11
• Enterprise Value/Revenue: 56.52
• Enterprise Value/Gross Profit: 56.52
• Enterprise Value/Ebitda: -4.11
• 1Y Price Target: $2.50
• Price Target Upside: 455.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $0.29 ▼(-36.44% Downside)

VolitionRX's overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. The technical analysis also indicates bearish momentum, further weighing down the score. While the earnings call provided some positive insights into strategic partnerships and revenue growth, these factors are not enough to offset the significant financial and technical challenges.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and successful product adoption, which can drive long-term business expansion and stability.

Strategic Partnerships

Partnerships with major companies like Werfen and Hologic enhance market reach and credibility, potentially leading to sustainable revenue streams and competitive advantages.

Cost Management

Effective cost management improves profitability and cash flow, providing financial flexibility to invest in growth opportunities and enhance long-term viability.

Negative Factors

Financial Instability

Negative equity and reliance on debt financing highlight potential solvency issues, which could limit strategic options and increase financial risk.

Cash Flow Challenges

Ongoing cash burn pressures financial resources, potentially hindering investment in R&D and expansion, affecting long-term growth prospects.

Unpredictable Revenue

Unpredictable revenue streams create uncertainty in financial planning and may impact the company's ability to achieve consistent growth and profitability.

VolitionRX Business Overview & Revenue Model

Company Description

VolitionRX (VNRX) is a biotechnology company focused on developing and commercializing innovative blood-based diagnostic tests for various cancers. The company operates primarily in the healthcare sector, leveraging its proprietary Nucleosomics technology to detect cancer through the analysis of nucleosomes—DNA fragments released by dying cells. VolitionRX aims to improve early cancer detection, thereby increasing treatment success rates and potentially saving lives with its core products designed for clinical use.

How the Company Makes Money

VolitionRX generates revenue primarily through the commercialization of its cancer diagnostic tests, which are sold to laboratories and healthcare providers. The company has established partnerships with various laboratories and healthcare institutions to facilitate the adoption of its tests in clinical settings. Additionally, VolitionRX may receive funding through grants and collaborations with research organizations or pharmaceutical companies, further supporting its product development and market expansion efforts. The revenue model is centered on test sales, with potential for recurring revenue as more healthcare providers adopt their diagnostics.

VolitionRX Financial Statement Overview

Summary

VolitionRX is facing significant financial challenges across all verticals. The company shows growth in revenue but struggles with profitability and cash flow management. The balance sheet reflects financial instability with negative equity, and cash flow statements indicate ongoing cash burn. While there are minor improvements in certain areas, the overall financial health remains weak, requiring strategic interventions to stabilize and improve financial performance.

Income Statement

VolitionRX's income statement reveals a challenging financial position with consistently negative net profit margins and EBIT margins over the years. Despite a positive revenue growth trend, the company struggles with profitability, as indicated by negative EBIT and EBITDA margins. The TTM data shows a slight improvement in net profit margin compared to previous years, but the overall profitability remains weak.

Balance Sheet

The balance sheet indicates significant financial instability, with negative stockholders' equity and a concerning debt-to-equity ratio. The negative equity suggests potential solvency issues, and the high return on equity is misleading due to negative equity values. The equity ratio is also negative, highlighting the company's reliance on debt financing.

Cash Flow

Cash flow analysis shows persistent negative operating and free cash flows, indicating cash burn issues. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow is somewhat aligned with net income, albeit negative. The TTM data shows a minor improvement in free cash flow growth, but overall cash flow health remains poor.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.47M	1.23M	775.30K	306.39K	90.03K	13.43K
Gross Profit	1.47M	1.23M	775.30K	306.39K	90.03K	13.43K
EBITDA	-20.26M	-25.58M	-34.04M	-29.24M	-25.69M	-19.23M
Net Income	-22.88M	-26.97M	-35.32M	-30.27M	-26.81M	-20.35M
Balance Sheet
Total Assets	6.45M	9.40M	27.95M	18.30M	27.49M	26.15M
Cash, Cash Equivalents and Short-Term Investments	199.41K	3.26M	20.73M	10.87M	20.58M	19.44M
Total Debt	11.26M	5.82M	5.86M	4.97M	4.02M	4.44M
Total Liabilities	42.40M	35.51M	36.66M	21.42M	9.77M	9.86M
Stockholders Equity	-34.64M	-24.91M	-7.80M	-2.57M	17.94M	16.34M
Cash Flow
Free Cash Flow	-19.74M	-26.47M	-19.15M	-16.85M	-21.83M	-18.41M
Operating Cash Flow	-19.47M	-25.89M	-18.06M	-15.28M	-20.85M	-16.46M
Investing Cash Flow	-276.45K	-573.85K	-1.08M	-1.57M	-973.56K	-1.65M
Financing Cash Flow	13.09M	8.66M	28.98M	6.94M	22.86M	20.62M

VolitionRX Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VNRX, the sentiment is Negative. The current price of 0.45 is above the 20-day moving average (MA) of 0.36, below the 50-day MA of 0.47, and below the 200-day MA of 0.57, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 34.15 is Neutral, neither overbought nor oversold. The STOCH value of 22.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VNRX.

VolitionRX Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	57 Neutral	$32.51M	-16.60	-9.76%	―	30.95%	59.67%
BNR	57 Neutral	$121.79M	-6.04	-19.87%	―	5.44%	72.17%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BDSX	46 Neutral	$60.46M	-1.42	-302.55%	―	22.29%	31.93%
TRIB	44 Neutral	$18.05M	-0.34	―	―	-4.35%	-6.31%
VNRX	42 Neutral	$39.51M	-1.41	―	―	14.48%	36.83%
BNGO	40 Underperform	$18.83M	―	-78.22%	―	-13.84%	88.80%

VolitionRX Corporate Events

VolitionRx Ltd. Earnings Call Highlights Growth and Partnerships

VolitionRx Ltd. recently held its earnings call, revealing a generally positive sentiment with notable achievements in revenue growth, cost management, and strategic partnerships. The company showcased its scientific advancements, which promise future potential, although challenges such as unpredictable revenue and uncertainties in licensing agreements persist.

VolitionRx Limited Reports Q3 2025 Financial Growth

VolitionRx Limited is a multi-national epigenetics company dedicated to advancing the science of epigenetics through the development and commercialization of simple, cost-effective blood tests for early disease detection and monitoring, focusing on critical areas such as cancer and sepsis.

VolitionRX Amends Underwriting Agreement for Stock Offering

On October 10, 2025, VolitionRx Limited entered into an Underwriting Agreement with Newbridge Securities Corporation for a public offering of 11,550,000 shares of common stock, along with warrants for an equal number of shares. The offering was priced at $0.52 per share, including a $0.01 warrant, with a 7% underwriting discount. On November 7, 2025, an amendment to the agreement allowed the underwriter to exercise an over-allotment option for 1,194,000 shares and 1,732,500 warrants at the same price, enhancing flexibility in the offering.

The most recent analyst rating on (VNRX) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on VolitionRX stock, see the VNRX Stock Forecast page.

VolitionRx Ltd. Earnings Call: Key Insights and Challenges

VolitionRx Ltd.’s recent earnings call conveyed a mixed sentiment, highlighting significant achievements in cost reduction, revenue growth, and product sales, alongside promising clinical study outcomes. The company also made notable strides in licensing and partnerships. However, concerns were raised regarding uncertain revenue projections and dwindling cash reserves.